According to filings with the U.S. Securities and Exchange Commission, Adela is raising $29,199,991.00 in new funding. Sources indicate that as part of senior management President, Scott Bratman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Adela
Adelas mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease. Adelas genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Networks Princess Margaret Cancer Centre. Adela is initially planning to develop the technology for use across the entire cancer continuum for detection, diagnosis and management of disease.

To learn more about Adela, visit http://www.adelabio.com

Contact:
Scott Bratman, President
888-210-1773

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.